Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1635
This examiner grants 45% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18414857 | TUMOR-INTRINSIC GALECTIN-3 SUPPRESSES MELANOMA METASTASIS | Non-Final OA | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES |
| 18540306 | ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTELl EXPRESSION | Final Rejection | HOFFMANN-LA ROCHE INC. |
| 18310891 | ALKENYL SUBSTITUTED 2,5-PIPERAZINEDIONES, COMPOSITIONS, AND USES THEREOF | Non-Final OA | Massachusetts Institute of Technology |
| 18248974 | RNA COMPOSITIONS AND METHODS FOR INHIBITING LIPOPROTEIN(A) | Non-Final OA | SANOFI |
| 17792705 | UNIVERSAL DYNAMIC PHARMACOKINETIC-MODIFYING ANCHORS | Final Rejection | UNIVERSITY OF MASSACHUSETTS |
| 17532636 | OLIGONUCLEOTIDES FOR DGAT2 MODULATION | Final Rejection | UNIVERSITY OF MASSACHUSETTS |
| 17101545 | HIGH THROUGHPUT GENE EDITING SYSTEM AND METHOD | Final Rejection | Recursion Pharmaceuticals, Inc. |
| 17611780 | ANGIOTENSIN II TYPE 1 RECEPTOR TARGETED OLIGONUCLEOTIDES AND USES THEREOF | Final Rejection | Ionis Pharmaceuticals, Inc. |
| 17055251 | Subcutaneous Delivery of Messenger RNA | Final Rejection | Translate Bio, Inc. |
| 17836265 | Modified Guide RNAs for Gene Editing | Non-Final OA | Intellia Therapeutics, Inc. |
| 17335818 | RNA-GUIDED CAS NUCLEASES AND USES THEREOF IN DIAGNOSTICS AND THERAPY | Final Rejection | UTAH STATE UNIVERSITY |
| 18504781 | Composition Comprising Antisense Oligonucleotide and Use Thereof for Treatment of Duchenne Muscular Dystrophy | Final Rejection | NIPPON SHINYAKU CO., LTD. |
| 18484970 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | Final Rejection | Sarepta Therapeutics, Inc. |
| 18037029 | SUPPRESSING HIPPO SIGNALING IN THE STEM CELL NICHE PROMOTES SKELETAL MUSCLE REGENERATION | Non-Final OA | Texas Heart Institute |
| 17925892 | Promoter Sequences for In Vitro and In Vivo Expression of Gene Therapy Products in CD3+ Cells | Final Rejection | Ixaka France |
| 17905881 | OLIGONUCLEOTIDE AND TARGET RNA SITE-SPECIFIC EDITING METHOD | Final Rejection | FREST Inc. |
| 17709485 | COMBINATION TREATMENTS FOR CYSTIC FIBROSIS CHARACTERIZED BY A 3849 + 10KB C-TO-T CFTR MUTATION | Final Rejection | SPLISENSE LTD. |
| 17607908 | RESTORATION OF THE CFTR FUNCTION BY SPLICING MODULATION | Non-Final OA | SpliSense Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy